Champlain Investment Partners’s Idexx Laboratories IDXX Stock Holding History

Champlain Investment Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-192,226	Closed	-$103M	–	139
2025 Q2	$103M	Sell	192,226 -32,379	-14%	-$15.5M	0.72%	55
2025 Q1	$94.3M	Buy	+224,605	New	+$97.5M	0.68%	59
2024 Q2	–	Sell	-94,221	Closed	-$50.9M	–	126
2024 Q1	$50.9M	Sell	94,221 -106,725	-53%	-$58.3M	0.29%	110
2023 Q4	$112M	Sell	200,946 -11,963	-6%	-$5.62M	0.66%	61
2023 Q3	$93.1M	Sell	212,909 -455	-0.2%	-$227K	0.6%	69
2023 Q2	$107M	Sell	213,364 -250	-0.1%	-$120K	0.66%	65
2023 Q1	$107M	Sell	213,614 -4,295	-2%	-$2.06M	0.67%	61
2022 Q4	$88.9M	Sell	217,909 -5,130	-2%	-$1.99M	0.57%	78
2022 Q3	$72.7M	Buy	223,039 +72,740	+48%	+$26.7M	0.5%	88
2022 Q2	$52.7M	Buy	+150,299	New	+$61.3M	0.34%	104

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Champlain Investment Partners's IDXX Position: Q3 2025 in Review

Champlain Investment Partners sold out of Idexx Laboratories (IDXX) in Q3 2025, closing a stake of 192,226 shares — an estimated $103M sold.

Champlain Investment Partners first reported a position in IDXX in Q2 2022 and held it in 10 quarters. The position peaked at $112M in Q4 2023. 1,303 funds tracked by Wall St. Rank hold IDXX as of Q3 2025.

Champlain Investment Partners reported no remaining Idexx Laboratories position as of Q3 2025 after selling out during the quarter.
Champlain Investment Partners sold 192,226 Idexx Laboratories shares in Q3 2025, an estimated $103M.
Champlain Investment Partners first reported a position in Idexx Laboratories in Q2 2022 and held it in 10 quarters.
Champlain Investment Partners's Idexx Laboratories position peaked at $112M in Q4 2023.
1,303 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2025.

Based on Champlain Investment Partners's 13F filing for Q3 2025, filed 12 Nov 2025.